Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis

Table 2 Mutual exclusivity and co-occurrence of the top 50 mutated genes in BLCA

A	B	Neither	A not B	B not A	Both	Log₂ odds ratio	p value	q value	Tendency
TP53	FGFR3	169	185	45	13	− 1.922	< 0.001	0.003	Mutual exclusivity
RB1	FGFR3	284	70	56	2	− 2.787	< 0.001	0.02	Mutual exclusivity
TP53	RB1	199	141	15	57	2.423	< 0.001	< 0.001	Co-occurrence
RYR1	AHNAK	337	33	25	17	2.796	< 0.001	< 0.001	Co-occurrence
BIRC6	ADGRV1	333	34	28	17	2.572	< 0.001	0.001	Co-occurrence
SYNE1	AHNAK	307	63	21	21	2.285	< 0.001	0.002	Co-occurrence
FGFR3	STAG2	317	38	37	20	2.173	< 0.001	0.002	Co-occurrence
KDM6A	STAG2	277	78	28	29	1.879	< 0.001	0.002	Co-occurrence
MUC16	BIRC6	272	89	23	28	1.896	< 0.001	0.003	Co-occurrence
TTN	MUC16	174	121	43	74	1.307	< 0.001	0.005	Co-occurrence

ISSN: 1477-7819